Nautilus Biotechnology, Inc. (NAUT) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.32
↑+96% vs avg
5yr avg: 1.18
30Y Low0.7·High1.6
ROE
↓
-32.3%
↑-23% vs avg
5yr avg: -26.3%
30Y Low-83%·High-17%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NAUT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nautilus Biotechnology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $366M | $246M | $211M | $374M | $224M | $438M | $359M | — | — |
| Enterprise Value | $384M | $264M | $214M | $389M | $140M | $282M | $327M | — | — |
| P/E Ratio → | -6.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.32 | 1.57 | 1.01 | 1.41 | 0.71 | 1.20 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NAUT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
NAUT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -32.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.3% | -32.3% | -29.9% | -21.9% | -17.1% | -30.1% | — | -83.4% | 12532.0% |
| ROA | -27.2% | -27.2% | -25.8% | -19.4% | -15.5% | -20.8% | -30.2% | -11.7% | 429.7% |
| ROIC | -26.0% | -26.0% | -24.8% | -22.3% | -21.8% | -51.7% | -10.2% | -5.0% | — |
| ROCE | -32.0% | -32.0% | -30.7% | -23.8% | -17.3% | -21.3% | -31.5% | -12.3% | -76.6% |
NAUT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $18M ($30M total debt minus $12M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.15 | 0.13 | 0.10 | 0.08 | — | 15.23 | 1.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 0.01 |
| Net Debt / Equity | — | 0.11 | 0.01 | 0.06 | -0.27 | -0.43 | — | 15.20 | 0.76 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 0.01 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -9.96 | — | — | — | — |
NAUT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Nautilus Biotechnology, Inc.'s current ratio of 13.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 19.39x to 13.33x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.33 | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 25.73 | 34.62 | 266.45 |
| Quick Ratio | 13.33 | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 25.73 | 34.62 | 266.45 |
| Cash Ratio | 13.00 | 13.00 | 17.02 | 19.01 | 27.16 | 59.49 | 25.43 | 34.00 | 999999.00 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
NAUT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nautilus Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $126M | $125M | $125M | $125M | $84M | $33M | $6M | $7M |
Peer Comparison
Compare NAUT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NAUTYou | $366M | -6.1 | — | — | — | — | -32.3% | -26.0% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 SEER | $105M | -1.4 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 QBTS | $8B | -19.8 | — | — | 82.6% | -408.2% | -77.6% | -102.0% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 BFLY | $1B | -13.7 | — | — | 46.9% | -88.5% | -42.2% | -76.8% | — |
 TWST | $4B | -45.0 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See NAUT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAUT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAUT vs CDNA
Side-by-side business, growth, and profitability comparison vs CareDx, Inc.
Start ComparisonNAUT — Frequently Asked Questions
Quick answers to the most common questions about buying NAUT stock.
What is Nautilus Biotechnology, Inc.'s P/E ratio?
Nautilus Biotechnology, Inc.'s current P/E ratio is -6.1x. This places it at the 50th percentile of its historical range.
What is Nautilus Biotechnology, Inc.'s ROE?
Nautilus Biotechnology, Inc.'s return on equity (ROE) is -32.3%. The historical average is -35.8%.
Is NAUT stock overvalued?
Based on historical data, Nautilus Biotechnology, Inc. is trading at a P/E of -6.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.